CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussingLexaria Bioscience (OTCQB:LXRP,CSE:LXX) recent product launches and the closing of the company’s private placement.
Lexaria Bioscience (OTCQB:LXRP,CSE:LXX) recently announced the launch of its TurboCBD™ brand of enhanced, high-absorption, full-spectrum hemp oil capsules. The capsules incorporate the company’s patented absorption technology — proven to increase CBD absorption by five to ten times compared to conventional preparations — along with the finest American Ginseng and Ginkgo Biloba to support enhanced focus and memory as well as reduced stress and fatigue.
The market for cannabidiol (“CBD”) is expected to grow to a $2.1 billion market in consumer sales by 2020, according to the Hemp Business Journal, with about $450 million of those sales coming from hemp-based sources. While there are plenty of companies involved in selling hemp-based CBD products, there are few options for solving the problems associated with the bioavailability of CBDs, which tends to be lacking in many products.
In addition to TurboCBD™, the company plans to launch other capsule formulations utilizing its patented absorption technology to address specific market demands. Management is also developing and seeking opportunities to leverage its technology for tetrahydrocannabinol (“THC”) product applications through licensees in the United States, Canada, and other countries around the world — potentially opening the door to new markets.
Lexaria has leveraged a combination of public and private capital to support the development of its innovative portfolio of products. With this combination, the company is able to offset some of its research and development expenses to bring products to market more quickly and effectively than ever possible.
On April 3, the company announced the completion of a brokered private placement of 4,104,280 units at a price of US$0.42 each for total gross proceeds of US$1,723,798. The units of the offering consist of one common share and one-half share purchase warrant at a price of US$0.60 per share for a 24-month period. The proceeds of the offering will be used to advance the research and development of its patented delivery technology.
In addition the company raised in excess of US$1 million in recent months from existing shareholders who have exercised existing warrants and stock options.
The most recent capital raise also marks the first time ever that the company has a runway of greater than one year, which will help limit future dilution. In fact, Lexaria is better capitalized today than at any point in its history, giving the company its best-ever opportunity to leverage its technology to the benefit of its B2B partners.
Looking Ahead
Lexaria Corp. (OTCQB: LXRP) is uniquely positioned to capture market share within the $2.1 billion CBD industry. With its innovative delivery system, the company’s products offer significantly enhanced bioavailability compared to competing products. The recent launch of new products and secured financing opens the door to significant revenue growth ahead and investors may want to keep a close eye on the stock.

About CFN Media


CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Click here to learn more about Lexaria Bioscience (OTCQB:LXRP,CSE:LXX).

Source: www.marketwired.com

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less